Opinion|Videos|September 3, 2024
ASCERTAIN Data: Oral Decitabine-Cedazuridine Outcomes in MDS
Medical experts discuss the data gathered from the ASCERTAIN trial.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Although oral decitabine-cedazuridine has been FDA approved for some time, the ASCERTAIN trial data are a recent advancement in our knowledge of this drug and its use in myelodysplastic syndromes (MDS). Briefly describe the ASCERTAIN trial design.
- What are some key takeaways regarding the outcomes of treating MDS with oral decitabine-cedazuridine compared with intravenous decitabine, according to the ASCERTAIN data?
Advertisement
Related to this article
Prior authorization and compounded drugs remain top obesity care access barriers, says NYU Langone's Holly Lofton, MD.
Panelists say IRA, Most Favored Nation rules and fragmented data are freezing value-based deals for durable one-time therapies.
Payers say NCCN guideline concordance sets a baseline for cancer coverage, but cost and formulary variation may still limit access.
FDA approved belzutifan plus lenvatinib for advanced ccRCC after PD-1/PD-L1 therapy, expanding treatment options for those with disease progression.
A 3-year registry found dupilumab controlled atopic dermatitis (AD) in most children, though those under 6 years were likelier to stop treatment.
Machine learning identified age, BMI, income, and reproductive factors as key predictors of overactive bladder risk among US women.
Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.
Boarding admitted patients on inpatient floor hallways can alleviate emergency department (ED) crowding. Outcomes tend to be positive, but the published evidence is weak, according to this systematic review.
Advertisement
Advertisement
Trending on AJMC
1
Surrogate End Points, Drug Costs Complicate Oncology Formularies
2
Perceptions About CGMs Among Primary Care Physicians and Endocrinologists
3
COVID-19 or Flu? Symptoms Alone Can't Tell: Tammy Lundstrom, MD, JD
4
Medicare Part D Ruxolitinib Spending Hits $49.6 Million as Use Surges
5